Boston Scientific's Guidant unit pleaded guilty Monday to two misdemeanor charges related to failure to properly report to the FDA some of the changes it made to its implantable defibrillators. U.S. District Judge Donovan Frank plans to issue a ruling within three weeks on the plea agreement, which calls for Guidant to pay a criminal penalty of more than $296 million.

Related Summaries